Showing 711-720 of 9595 results for "".
Toxic Attitudes Toward Skin Bleaching
https://practicaldermatology.com/conferences/aad-2021/toxic-attitudes-toward-skin-bleaching/19925/Unregulated ingredients intended for skin lightening and bleaching range from the toxic to the simply unproven. Seemal Desai, MD says dermatologists should educate patients about physician-recommended, well-studied treatments and the risks of unregulated products. He highlights increased attention tThe Acne Therapy Pipeline
https://practicaldermatology.com/topics/acne-rosacea/the-acne-therapy-pipeline/19724/From new agents to improved formulations, Lawrence Eichenfield, MD breaks down the latest advances in acne therapy.Education is Essential
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/education-is-essential/19680/How do you integrate aesthetics into a new practice, and how do you get patients to understand the basics of skincare? Heidi Prather, MD says that education of both staff and patients is key.Elastin - The underappreciated skin fundamental
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/elastin-the-underappreciated-skin-fundamental/19672/Join Macrene Alexiades, MD, PhD, FAAD as she discusses elastin and its role as a critical, yet often underappreciated, skin fundamental. In this webinar, she explains why lack of elastin is the root cause of skin laxity and what happens when there is a cessation of elastin synthesis. Dr. Alexiades rDermWireTV: AbbVie to Acquire Allergan, Duobrii Launches, SDPA at 25
https://practicaldermatology.com/topics/psoriasis/dermwiretv-abbvie-to-acquire-allergan-duobrii-launches-sdpa-at-25/19629/In a deal with an equity value of approximately $63 billion, AbbVie has agreed to acquire Allergan. The new company is positioned for new growth platforms and a diversified revenue base; the deal will be immediately accretive to earnings per share, AbbVie says. The Society of Dermatology Physician APrivate Equity in Dermatology: An Inside View
https://practicaldermatology.com/topics/practice-management/private-equity-in-dermatology-an-inside-view/18219/Private equity firms are turning their attention to the dermatology specialty. Why? How has the market changed and what may be on the horizon? An investment banker with knowledge of the field weighs in with an overview from him perspective.What is the most important thing you do every morning?
https://practicaldermatology.com/topics/practice-management/what-is-the-most-important-thing-you-do-every-morning/18566/Adam Friedman, MD shares what he does every morning to set the tone and mentally prepare for the day. Watch other PD Asks videos with Adam Friedman, MD, FAAD: In a movie about your practice, who would play you? What is the best "prop" or fixture in your exam rooms that facilitates patient interaDifferin Goes OTC, ISDIN Comes to America, Understand AD
https://practicaldermatology.com/topics/psoriasis/dermwiretv-differin-goes-otc-isdin-comes-to-america-understand-ad/18762/Barcelona-based ISDIN is officially operating in the US. The company—which operates in Europe, Latin America, and Asia—is bringing its skincare products to the US market. Regeneron Pharmaceuticals, Sanofi Genzyme, the National Eczema Association, and the Dermatology Nurses Association launch UnderASDS BCC Recommendations; Bad Online Reviews for Derms
https://practicaldermatology.com/topics/practice-management/dermwiretv-asds-bcc-recommendations-bad-online-reviews-for-derms/18906/This edition of DermWireTV, from the editors of Practical Dermatology® magazine reviews the new ASDS Consensus Recommendation for the management of Basal Cell Carcinoma (BCC). An expert panel found Mohs micrographic surgery is highly cost effective. In other news, researchers find that dermatologistAllergan Strikes $66 Billion Deal with Actavis
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-allergan-strikes-66-billion-deal-with-actavis/19021/In this edition of DermWireTV, host Ranna Jaraha discusses this week's blockbuster merger deal between Allergan and Actavis. Also featured in this edition is a new report detailing the rising costs of treating skin cancer, and high recognition for a dermatologic device manufacturer.